BACKGROUND: Dominant biliary strictures occur commonly in patients with primary sclerosing cholangitis (PSC), who have a high risk of developing cholangiocarcinoma (CC). The natural history and optimal management of dominant strictures remain unclear, with some reports suggesting that endoscopic interventions improve outcome. METHODS: We describe a 25-year experience in patients with PSC-related dominant strictures at a single tertiary referral centre. RESULTS: A total of 128 patients with PSC (64% men, mean age at referral 49 years) were followed for a mean of 9.8 years. Eighty patients (62.5%) with dominant biliary strictures had a median of 3 (range 0-34) interventions, compared with 0 (0-7) in the 48 patients without dominant strictures (P<0.001). Endoscopic interventions included the following: (i) stenting alone (46%), (ii) dilatation alone (20%), (iii) dilatation and stenting (17%) and (iv) none or failed intervention (17%, of whom most required percutaneous transhepatic drainage). The major complication rate for endoscopic retrograde cholangiopancreatography was low (1%). The mean survival of those with dominant strictures (13.7 years) was worse than that for those without dominant strictures (23 years), with much of the survival difference related to a 26% risk of CC developing only in those with dominant strictures. Half of those with CC presented within 4 months of the diagnosis of PSC, highlighting the importance of a thorough evaluation of new dominant strictures. CONCLUSION: Repeated endoscopic therapy in PSC patients is safe, but the prognosis remains worse in the subgroup with dominant strictures. In our series, dominant strictures were associated with a high risk of developing CC.
BACKGROUND: Dominant biliary strictures occur commonly in patients with primary sclerosing cholangitis (PSC), who have a high risk of developing cholangiocarcinoma (CC). The natural history and optimal management of dominant strictures remain unclear, with some reports suggesting that endoscopic interventions improve outcome. METHODS: We describe a 25-year experience in patients with PSC-related dominant strictures at a single tertiary referral centre. RESULTS: A total of 128 patients with PSC (64% men, mean age at referral 49 years) were followed for a mean of 9.8 years. Eighty patients (62.5%) with dominant biliary strictures had a median of 3 (range 0-34) interventions, compared with 0 (0-7) in the 48 patients without dominant strictures (P<0.001). Endoscopic interventions included the following: (i) stenting alone (46%), (ii) dilatation alone (20%), (iii) dilatation and stenting (17%) and (iv) none or failed intervention (17%, of whom most required percutaneous transhepatic drainage). The major complication rate for endoscopic retrograde cholangiopancreatography was low (1%). The mean survival of those with dominant strictures (13.7 years) was worse than that for those without dominant strictures (23 years), with much of the survival difference related to a 26% risk of CC developing only in those with dominant strictures. Half of those with CC presented within 4 months of the diagnosis of PSC, highlighting the importance of a thorough evaluation of new dominant strictures. CONCLUSION: Repeated endoscopic therapy in PSCpatients is safe, but the prognosis remains worse in the subgroup with dominant strictures. In our series, dominant strictures were associated with a high risk of developing CC.
Authors: M Kaya; B T Petersen; P Angulo; T H Baron; J C Andrews; C J Gostout; K D Lindor Journal: Am J Gastroenterol Date: 2001-04 Impact factor: 10.864
Authors: Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé Journal: J Hepatol Date: 2002-03 Impact factor: 25.083
Authors: Michael H Chapman; Robert Tidswell; James S Dooley; Neomal S Sandanayake; Virginie Cerec; Maesha Deheragoda; Alvin J X Lee; Charles Swanton; Fausto Andreola; Stephen P Pereira Journal: J Hepatol Date: 2011-12-13 Impact factor: 25.083
Authors: C Y Ponsioen; S M E Vrouenraets; W Prawirodirdjo; R Rajaram; E A J Rauws; C J J Mulder; J B Reitsma; S H Heisterkamp; G N J Tytgat Journal: Gut Date: 2002-10 Impact factor: 23.059
Authors: Rungsun Rerknimitr; Evan L Fogel; Cem Kalayci; Edward Esber; Glen A Lehman; Stuart Sherman Journal: Gastrointest Endosc Date: 2002-12 Impact factor: 9.427